14990788 15680515 36517522 36336145 21426008 25127148 19496086 21728983 17125202 16107136 15709961 16101408 20105132 17438066 18668687 15862525 16300737 15857131 - Search Results

Year	Number of Results
2004	1
2005	7
2006	2
2007	1
2008	1
2009	1
2010	2
2011	1
2014	1
2022	2
2023	1

1

Expression and activation of the farnesoid X receptor in the vasculature.

Bishop-Bailey D, Walsh DT, Warner TD. Bishop-Bailey D, et al. Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3668-73. doi: 10.1073/pnas.0400046101. Epub 2004 Feb 27. Proc Natl Acad Sci U S A. 2004. PMID: 14990788 Free PMC article.

2

Crossing the line between activation and repression.

Ma J. Ma J. Trends Genet. 2005 Jan;21(1):54-9. doi: 10.1016/j.tig.2004.11.004. Trends Genet. 2005. PMID: 15680515

3

Unconventional isoquinoline-based SERMs elicit fulvestrant-like transcriptional programs in ER+ breast cancer cells.

Hancock GR, Young KS, Hosfield DJ, Joiner C, Sullivan EA, Yildiz Y, Lainé M, Greene GL, Fanning SW. Hancock GR, et al. NPJ Breast Cancer. 2022 Dec 14;8(1):130. doi: 10.1038/s41523-022-00497-9. NPJ Breast Cancer. 2022. PMID: 36517522 Free PMC article.

4

ESR1 activating mutations: From structure to clinical application.

Grinshpun A, Chen V, Sandusky ZM, Fanning SW, Jeselsohn R. Grinshpun A, et al. Biochim Biophys Acta Rev Cancer. 2023 Jan;1878(1):188830. doi: 10.1016/j.bbcan.2022.188830. Epub 2022 Nov 4. Biochim Biophys Acta Rev Cancer. 2023. PMID: 36336145 Free article. Review.

5

Antidiabetic sulfonylureas modulate farnesoid X receptor activation and target gene transcription.

Steri R, Kara M, Proschak E, Steinhilber D, Schneider G, Schubert-Zsilavecz M. Steri R, et al. Future Med Chem. 2010 Apr;2(4):575-86. doi: 10.4155/fmc.10.10. Future Med Chem. 2010. PMID: 21426008

6

Some molecular targets for antihyperlipidemic drug research.

Arya N, Kharjul MD, Shishoo CJ, Thakare VN, Jain KS. Arya N, et al. Eur J Med Chem. 2014 Oct 6;85:535-68. doi: 10.1016/j.ejmech.2014.08.013. Epub 2014 Aug 7. Eur J Med Chem. 2014. PMID: 25127148 Review.

7

Dietary procyanidins enhance transcriptional activity of bile acid-activated FXR in vitro and reduce triglyceridemia in vivo in a FXR-dependent manner.

Del Bas JM, Ricketts ML, Vaqué M, Sala E, Quesada H, Ardevol A, Salvadó MJ, Blay M, Arola L, Moore DD, Pujadas G, Fernandez-Larrea J, Bladé C. Del Bas JM, et al. Mol Nutr Food Res. 2009 Jul;53(7):805-14. doi: 10.1002/mnfr.200800364. Mol Nutr Food Res. 2009. PMID: 19496086 Free PMC article.

8

Peptides targeting estrogen receptor alpha-potential applications for breast cancer treatment.

Leclercq G, Gallo D, Cossy J, Laïos I, Larsimont D, Laurent G, Jacquot Y. Leclercq G, et al. Curr Pharm Des. 2011;17(25):2632-53. doi: 10.2174/138161211797416048. Curr Pharm Des. 2011. PMID: 21728983 Review.

9

Recognition of LXXLL by ligand binding domain of the Farnesoid X receptor in molecular dynamics simulation.

Zhang T, Dong XC, Chen MB. Zhang T, et al. J Chem Inf Model. 2006 Nov-Dec;46(6):2623-30. doi: 10.1021/ci060112v. J Chem Inf Model. 2006. PMID: 17125202

10

Farnesoid X receptor: from structure to potential clinical applications.

Pellicciari R, Costantino G, Fiorucci S. Pellicciari R, et al. J Med Chem. 2005 Aug 25;48(17):5383-403. doi: 10.1021/jm0582221. J Med Chem. 2005. PMID: 16107136 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results